• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

by MM360 Staff | Oct 15, 2025 | Uncategorized

Source: CURE articles Post Content Read More

by MM360 Staff | Sep 30, 2025 | Uncategorized

Source: CURE articles Post Content Read More

by MM360 Staff | Sep 26, 2025 | Uncategorized

Source: CURE articles Post Content Read More

by MM360 Staff | Sep 24, 2025 | Uncategorized

Source: CURE articles Post Content Read More

Beyond the Diagnosis: A Stage-by-Stage Guide to Multiple Myeloma Treatment

by MM360 Staff | Sep 19, 2025 | Uncategorized

Source: CureToday articles Diagnosed with multiple myeloma? Our guide explains each stage and treatment, helping you engage confidently with your care team. Read More

Looking Back on the Shock of a Multiple Myeloma Diagnosis

by MM360 Staff | Sep 19, 2025 | Uncategorized

Source: CureToday articles What is the first emotion that comes to mind about your cancer journey? For me, the strong emotion that I choose is shock! Read More
« Older Entries

Recent Content

  • (no title)
  • Multiple myeloma incidence, transplant utilization, and mortality- impact of social vulnerability
  • Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis
  • Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT